日本ケミファの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/04/07 | 1,780 | 1,794 | 1,780 | 1,782 | +9 | +0.5% | 2,900 |
2023/04/06 | 1,817 | 1,817 | 1,773 | 1,773 | -28 | -1.6% | 3,100 |
2023/04/05 | 1,819 | 1,820 | 1,801 | 1,801 | -37 | -2% | 3,600 |
2023/04/04 | 1,835 | 1,846 | 1,835 | 1,838 | +9 | +0.5% | 5,700 |
2023/04/03 | 1,839 | 1,840 | 1,829 | 1,829 | -10 | -0.5% | 3,000 |
2023/03/31 | 1,841 | 1,847 | 1,816 | 1,839 | -6 | -0.3% | 3,300 |
2023/03/30 | 1,876 | 1,876 | 1,835 | 1,845 | +39 | +2.2% | 8,900 |
2023/03/29 | 1,790 | 1,806 | 1,790 | 1,806 | +4 | +0.2% | 3,200 |
2023/03/28 | 1,797 | 1,810 | 1,797 | 1,802 | -1 | -0.1% | 3,000 |
2023/03/27 | 1,795 | 1,807 | 1,791 | 1,803 | +27 | +1.5% | 3,800 |
2023/03/24 | 1,770 | 1,776 | 1,770 | 1,776 | +4 | +0.2% | 1,600 |
2023/03/23 | 1,764 | 1,780 | 1,763 | 1,772 | +8 | +0.5% | 2,500 |
2023/03/22 | 1,773 | 1,773 | 1,752 | 1,764 | +12 | +0.7% | 5,300 |
2023/03/20 | 1,757 | 1,775 | 1,744 | 1,752 | -45 | -2.5% | 5,800 |
2023/03/17 | 1,770 | 1,815 | 1,770 | 1,797 | +27 | +1.5% | 3,400 |
2023/03/16 | 1,765 | 1,775 | 1,764 | 1,770 | -12 | -0.7% | 2,200 |
2023/03/15 | 1,771 | 1,804 | 1,771 | 1,782 | +11 | +0.6% | 4,500 |
2023/03/14 | 1,784 | 1,784 | 1,768 | 1,771 | -26 | -1.4% | 3,500 |
2023/03/13 | 1,801 | 1,801 | 1,783 | 1,797 | -4 | -0.2% | 4,500 |
2023/03/10 | 1,793 | 1,807 | 1,792 | 1,801 | +2 | +0.1% | 8,500 |
2023/03/09 | 1,798 | 1,799 | 1,787 | 1,799 | +5 | +0.3% | 2,500 |
2023/03/08 | 1,791 | 1,794 | 1,783 | 1,794 | +3 | +0.2% | 3,000 |
2023/03/07 | 1,797 | 1,798 | 1,790 | 1,791 | -8 | -0.4% | 1,400 |
2023/03/06 | 1,799 | 1,803 | 1,790 | 1,799 | +6 | +0.3% | 5,400 |
2023/03/03 | 1,772 | 1,800 | 1,772 | 1,793 | +21 | +1.2% | 4,700 |
2023/03/02 | 1,766 | 1,783 | 1,766 | 1,772 | -15 | -0.8% | 3,300 |
2023/03/01 | 1,761 | 1,796 | 1,761 | 1,787 | +39 | +2.2% | 10,700 |
2023/02/28 | 1,755 | 1,755 | 1,746 | 1,748 | -13 | -0.7% | 2,400 |
2023/02/27 | 1,755 | 1,761 | 1,750 | 1,761 | +21 | +1.2% | 4,800 |
2023/02/24 | 1,742 | 1,744 | 1,738 | 1,740 | -2 | -0.1% | 1,500 |
2023/02/22 | 1,739 | 1,748 | 1,738 | 1,742 | -2 | -0.1% | 1,900 |
2023/02/21 | 1,755 | 1,755 | 1,743 | 1,744 | +1 | +0.1% | 2,400 |
2023/02/20 | 1,733 | 1,756 | 1,733 | 1,743 | +20 | +1.2% | 2,500 |
2023/02/17 | 1,732 | 1,735 | 1,723 | 1,723 | -4 | -0.2% | 800 |
2023/02/16 | 1,732 | 1,737 | 1,719 | 1,727 | -10 | -0.6% | 6,200 |
2023/02/15 | 1,737 | 1,742 | 1,727 | 1,737 | -17 | -1% | 4,400 |
2023/02/14 | 1,729 | 1,762 | 1,727 | 1,754 | +8 | +0.5% | 5,600 |
2023/02/13 | 1,750 | 1,753 | 1,735 | 1,746 | ±0 | ±0% | 6,100 |
2023/02/10 | 1,731 | 1,763 | 1,730 | 1,746 | +15 | +0.9% | 7,000 |
2023/02/09 | 1,737 | 1,741 | 1,731 | 1,731 | -6 | -0.3% | 5,800 |
2023/02/08 | 1,706 | 1,737 | 1,706 | 1,737 | +26 | +1.5% | 1,400 |
2023/02/07 | 1,712 | 1,725 | 1,711 | 1,711 | ±0 | ±0% | 4,100 |
2023/02/06 | 1,708 | 1,711 | 1,700 | 1,711 | +3 | +0.2% | 1,200 |
2023/02/03 | 1,703 | 1,714 | 1,700 | 1,708 | +2 | +0.1% | 2,700 |
2023/02/02 | 1,720 | 1,720 | 1,690 | 1,706 | -2 | -0.1% | 6,600 |
2023/02/01 | 1,734 | 1,734 | 1,693 | 1,708 | -80 | -4.5% | 12,000 |
2023/01/31 | 1,760 | 1,789 | 1,760 | 1,788 | +33 | +1.9% | 5,100 |
2023/01/30 | 1,758 | 1,787 | 1,755 | 1,755 | +9 | +0.5% | 20,900 |
2023/01/27 | 1,749 | 1,755 | 1,742 | 1,746 | ±0 | ±0% | 3,000 |
2023/01/26 | 1,740 | 1,758 | 1,733 | 1,746 | +9 | +0.5% | 6,600 |
401~
450
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム